{"id":"consolidation-i-ham-cycle","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a chemotherapy regimen used in consolidation therapy for acute myeloid leukemia (AML). Idarubicin and mitoxantrone are anthracycline topoisomerase II inhibitors that intercalate DNA and prevent strand separation, while high-dose cytarabine is a nucleoside analog that inhibits DNA synthesis. Together, these agents work synergistically to eliminate residual leukemic blasts after initial induction therapy.","oneSentence":"The I-HAM consolidation cycle combines idarubicin, high-dose cytarabine, and mitoxantrone to induce cytotoxic effects in acute myeloid leukemia cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:07:27.119Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML) consolidation therapy"}]},"trialDetails":[{"nctId":"NCT02072811","phase":"PHASE3","title":"Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"dr hab. n. med. Agnieszka Wierzbowska","startDate":"2014-02","conditions":"Acute Myeloid Leukemia","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["- Mitoxantrone","- Cytosine arabinoside [Ara-C]"],"phase":"phase_3","status":"active","brandName":"Consolidation, I HAM cycle","genericName":"Consolidation, I HAM cycle","companyName":"dr hab. n. med. Agnieszka Wierzbowska","companyId":"dr-hab-n-med-agnieszka-wierzbowska","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The I-HAM consolidation cycle combines idarubicin, high-dose cytarabine, and mitoxantrone to induce cytotoxic effects in acute myeloid leukemia cells. Used for Acute myeloid leukemia (AML) consolidation therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}